Humacyte’s Promising Growth: Strong Financials and Successful Symvess Launch Drive Buy Rating

Benchmark Co. analyst Bruce Jackson has reiterated their bullish stance on HUMA stock, giving a Buy rating yesterday.

Bruce Jackson has given his Buy rating due to a combination of factors that highlight Humacyte’s promising market position and financial performance. The company successfully launched its product, Symvess, in February and has already begun generating revenue, which was unexpected for the first quarter of 2025. This launch has been well-received, with 45 hospitals initiating the process to adopt the product, covering a significant portion of Level 1 trauma centers in the U.S.
Additionally, Humacyte’s financial health appears robust, with strong gross margins of 71.6% and a solid cash position of $62.8 million, excluding restricted cash. The company has also taken strategic steps to extend its cash runway by reducing its workforce and deferring new hires. These factors, combined with a promising pipeline of new products and a supportive economic model for Symvess, underpin Jackson’s confidence in the company’s future growth and market share expansion.

According to TipRanks, Jackson is an analyst with an average return of -20.5% and a 29.00% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Humacyte, Harvard Bioscience, and Genelux Corp..

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.